Experimental Hematology Group

Home Tag

Banner web VHIO (1300 × 600 px) (50)

Treatment with bendamustine prior to CAR T-cell therapy in patients with refractory large B-cell lymphoma associates with poorer treatment outcomes

Led by investigators of the Vall d’Hebron Institute of Oncology’s (VHIO) Experimental Hematology Group and the Advanced Therapies Program of…

Pere-Barba

Novel platform shows preclinical and early clinical promise in accelerating the production of more effective CAR-T cell therapy

Co-authored by Pere Barba, a Lead Investigator of VHIO’s Experimental Hematology Group, results of a study published in Cancer Discovery…

Dr. Pere Barba, Dra. Mònica Linares i Dra. Josefina Cortés amb una pacient amb lupus

Vall d’Hebron includes its first patient in a pioneering study into the use of CAR T-cell therapy for lupus

CAR T-cell therapy consists of targeted immune system cell modification to attack the cells that produce the antibodies causing the…

21_07_09_Francesc-Bosch

The immune microenvironment as a driver of disease progression in chronic lymphocytic leukemia

Research led by VHIO investigators represents a step forward in better understanding the underlying mechanisms that drive disease progression in…